ROYAL BANK OF CANADA - CATABASIS PHARMACEUTICALS IN ownership

CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 59 filers reported holding CATABASIS PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of CATABASIS PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$4,000
-42.9%
1,915
-27.6%
0.00%
Q1 2021$7,000
+133.3%
2,644
+53.7%
0.00%
Q4 2020$3,000
+200.0%
1,720
+1790.1%
0.00%
Q3 2020$1,0000.0%91
+1.1%
0.00%
Q2 2020$1,00090
-1.1%
0.00%
Q1 2020$0
-100.0%
91
-3.2%
0.00%
Q4 2019$1,0000.0%94
-51.3%
0.00%
Q3 2019$1,0000.0%193
+114.4%
0.00%
Q2 2019$1,0000.0%900.0%0.00%
Q1 2019$1,000900.0%0.00%
Q4 2018$0900.00%
Other shareholders
CATABASIS PHARMACEUTICALS IN shareholders Q2 2021
NameSharesValueWeighting ↓
Fairmount Funds Management LLC 4,092,166$8,634,0003.55%
COMMODORE CAPITAL LP 1,617,000$3,412,0001.19%
ACUTA CAPITAL PARTNERS, LLC 1,173,674$2,476,0000.99%
VR Adviser, LLC 3,234,000$6,824,0000.83%
Logos Global Management LP 3,190,000$6,731,0000.57%
Cormorant Asset Management, LP 3,550,000$7,490,0000.25%
Soleus Capital Management, L.P. 775,000$1,635,0000.25%
Perceptive Advisors 15,374,370$32,438,0000.21%
RA Capital Management 5,947,861$12,550,0000.20%
SILVERARC CAPITAL MANAGEMENT, LLC 188,777$398,0000.18%
View complete list of CATABASIS PHARMACEUTICALS IN shareholders